Axcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
Axcella Therapeutics (Nasdaq: AXLA) announced its participation in the H.C. Wainwright 6th Annual NASH Investor Conference on October 17, 2022. The company's management will engage in a fireside chat and hold one-on-one meetings, starting at 3:00 PM Eastern Time. Investors can access the webcast through the company’s website, with an archived replay available for 90 days. Axcella focuses on multi-targeted endogenous metabolic modulators to treat complex diseases, with significant developments in therapies for Long COVID and NASH.
- None.
- None.
Details for the fireside chat are as follows:
Date: |
|
||
Time: |
|
||
Webcast: |
https://journey.ct.events/view/6b38c477-2942-428b-aed6-b4f7a0dcea88 |
The webcast will be accessible in the Investors & News section on the company’s website at www.axcellatx.com. An archive of the webcast replay will be available on the Company’s website for up to 90 days.
To request a one-on-on virtual meeting, please contact meetings@hcwco.com.
Internet Posting of Information
Axcella uses the “Investors and News” section of its website, www.axcellatx.com, as a means of disclosing material nonpublic information, to communicate with investors and the public, and for complying with its disclosure obligations under Regulation FD. Such disclosures include, but may not be limited to, investor presentations and FAQs,
About Axcella Therapeutics (Nasdaq: AXLA)
Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). The company’s product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to reset multiple biological pathways, improve cellular energetics, and restore homeostasis. Axcella’s pipeline includes lead therapeutic candidates in Phase 2 development for the treatment of Long COVID and NASH. The company’s unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit www.axcellatx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221014005467/en/
arr@lifesciadvisors.com
(617) 430-7577
Source: Axcella Therapeutics
FAQ
When is Axcella Therapeutics participating in the NASH Investor Conference?
How can I access the Axcella Therapeutics webcast for the NASH Investor Conference?
What is the focus of Axcella Therapeutics?
What is the stock symbol for Axcella Therapeutics?